NCT03855683

Brief Summary

The purpose of this study is to identify cognitive mechanisms that might facilitate treatment response for individuals experiencing depression and/or anxiety. The Stress, Anxiety, and Mood group helps individuals experiencing symptoms of stress, anxiety, and mood by providing concrete coping skills to regulate emotions, to let go of negative thoughts, and build courage to talk to others about tough topics. Groups meet for 8 weeks, with sessions lasting 90 minutes each. In addition to group therapy, you will be asked to complete some computerized and paper and pencil-based tasks. If you are interested in learning more, please contact us at 650-417-2000 ext. 3642 or paloalto.study@gmail.com. All inquiries will be kept strictly confidential.

Trial Health

33
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Trial recruitment is currently suspended
Enrollment
50

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Mar 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
suspended

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

February 10, 2019

Completed
17 days until next milestone

First Posted

Study publicly available on registry

February 27, 2019

Completed
7 days until next milestone

Study Start

First participant enrolled

March 6, 2019

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 1, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

February 1, 2022

Completed
Last Updated

September 18, 2020

Status Verified

September 1, 2020

Enrollment Period

2.9 years

First QC Date

February 10, 2019

Last Update Submit

September 16, 2020

Conditions

Keywords

depressionanxiety

Outcome Measures

Primary Outcomes (12)

  • Level of depression as measured by the following questionnaire:

    Mood and Anxiety Symptom Questionnaire- Anhedonic Depression subscale

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of intolerance of uncertainty as measured by the following questionnaire:

    Intolerance of Uncertainty Questionnaire

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of rumination and reflection as measured by the following questionnaire:

    Rumination Reflection Questionnaire

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of anxious arousal as measured by the following questionnaire:

    Mood and Anxiety Symptom Questionnaire- Anxious Apprehension subscale

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of anxious apprehension as measured by the following questionnaire:

    Penn State Worry Questionnaire

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of alcohol use as measured by the following questionnaire:

    Alcohol Use Disorders Identification Test

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of positive and negative emotions as measured by the following questionnaire:

    The Positive and Negative Affect Schedule

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of behavioral regulation and metacognition as measured by the following questionnaire:

    Behavioral Regulation Index and Metacognition Index

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of trait mood as measured by the following questionnaire:

    Trait Meta-Mood Scale.

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of emotion regulation as measured by the following questionnaire:

    Emotion Regulation Questionnaire

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of mental imagery as measured by the following questionnaire:

    Questionnaire of Mental Imagery

    The change from baseline and post-treatment, approximately 8 weeks after baseline

  • Level of cognitive functioning via neuropsychological testing session

    Objective assessment of cognitive strengths and weaknesses

    Baseline

Study Arms (1)

Group therapy (Unified Protocol)

EXPERIMENTAL

Participants experiencing stress, anxious, and/or depressive symptoms will receive 8 sessions of Unified Protocol for Emotional Disorders lasting for 90 minutes each. Includes psycho-education about (mal)adaptive emotion regulation, cognitive and behavioral tools to reduce symptoms of stress, anxiety, and/or depression.

Behavioral: Unified Protocol for The Treatment of Emotional Disorders

Interventions

Unified Protocol (UP) is is an 8-week intervention designed to specifically benefit individuals who report co-occurring symptoms of anxiety, stress, and mood by providing them with psychoeducation regarding (mal)adaptive emotion regulation, as well as with skills for effectively responding to stress. UP is based on a cognitive-behavioral framework and uses cognitive and behavioral therapy techniques. Each session of UP group therapy is 90 minutes in duration. Sessions themselves generally include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities.

Group therapy (Unified Protocol)

Eligibility Criteria

Age18 Years - 50 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Normal color vision
  • Ability to travel to Palo Alto University
  • Experiencing symptoms of stress, anxiety, and/or depression

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Palo Alto University

Los Altos, California, 94022, United States

Location

MeSH Terms

Conditions

Depressive DisorderAnxiety DisordersDepression

Condition Hierarchy (Ancestors)

Mood DisordersMental DisordersBehavioral SymptomsBehavior

Study Officials

  • Stacie Warren, PhD

    Palo Alto University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Principal Investigator

Study Record Dates

First Submitted

February 10, 2019

First Posted

February 27, 2019

Study Start

March 6, 2019

Primary Completion

February 1, 2022

Study Completion

February 1, 2022

Last Updated

September 18, 2020

Record last verified: 2020-09

Data Sharing

IPD Sharing
Will not share

Locations